Single Cell Sequencing and Multidimensional Omics Studies in Cardiovascular and Neurological Diseases
Tao Xin
400 participants
Apr 1, 2023
OBSERVATIONAL
Conditions
Summary
Research purpose Using single-cell sequencing, 3D/4D genomics and multidimensional omics technologies to reveal the complex cellular and molecular regulatory networks of cardiovascular and nervous system diseases, unique phenotypic changes of specific cell types, and different gene expression patterns, identify cell types and cell subsets associated with cardiovascular and nervous system diseases, and discover disease-related genes. To reveal new pathological mechanisms of related diseases and develop new diagnosis and treatment methods. Research background Cardiovascular and nervous system diseases such as arrhythmias (atrial fibrillation, ventricular tachycardia, ventricular fibrillation, postoperative vascular stenosis injury, etc.), heart failure, atherosclerosis (coronary heart disease, stroke, peripheral vascular disease, carotid atherosclerosis, etc.), epilepsy, moyamoya disease, etc., are currently leading to the main diseases affecting the health and death of residents in China. The data integration method based on single-cell sequencing, multi-omics data, and machine learning to analyze molecular level changes in cardiovascular and nervous system-related diseases can help deepen the research on the pathogenesis of cardiovascular and nervous system-related diseases and provide new ideas for the prevention and treatment of related diseases.
Eligibility
Inclusion Criteria5
- Moderate or above mitral valve disease; The occurrence of atrial fibrillation was recorded by 12-lead electrocardiogram or 24-hour holter electrocardiogram. 3.18≤ Age ≤75 years old.
- No moderate or above mitral valve disease; No history of atrial fibrillation, 24-hour holter electrocardiogram did not record the occurrence of atrial fibrillation. 3.18≤ Age ≤75 years old.
- Carotid atherosclerosis was confirmed by ultrasound, CTA and other imaging diagnosis. 2.18≤ Age ≤75 years old.
- Imaging diagnosis confirmed moyamoya disease; 2.18≤ Age ≤75 years old.
- Imaging diagnosis confirmed no moyamoya disease; 2.18≤ Age ≤75 years old.
Exclusion Criteria6
- Coronary heart disease, myocardial infarction, hyperthyroidism, severe hepatic and renal insufficiency, benign and malignant tumors, etc. Dilated cardiomyopathy, hypertrophic cardiomyopathy, congenital heart disease, heart failure and other non-valvular factors cause atrial fibrillation.
- Coronary heart disease, myocardial infarction, hyperthyroidism, severe hepatic and renal insufficiency, benign and malignant tumors, etc. Dilated cardiomyopathy, hypertrophic cardiomyopathy, congenital heart disease, heart failure, etc.
- History of carotid vascular surgery or trauma
- No plaque margin tissue or marginal tissue injury was found in abandoned vessels in the same patient.
- Previous history of cerebrovascular surgery or trauma.
- Previous history of cerebrovascular surgery or trauma.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06114095